These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29226417)

  • 1. Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease-Author's reply.
    Selinger CP; Parkes GC; Raine T
    Aliment Pharmacol Ther; 2018 Jan; 47(1):145. PubMed ID: 29226417
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease-author's reply.
    McCurdy JD
    Aliment Pharmacol Ther; 2019 Sep; 50(6):714-715. PubMed ID: 31456301
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease.
    Colizzo FP; Friedman LS
    Aliment Pharmacol Ther; 2018 Jan; 47(1):143-144. PubMed ID: 29226421
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with inflammatory bowel disease-authors' reply.
    Rosiou K; Selinger CP
    Aliment Pharmacol Ther; 2022 Sep; 56(5):898-899. PubMed ID: 35934863
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator? Author's reply.
    Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1168. PubMed ID: 28326587
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of inflammatory bowel disease with corticosteroids.
    Katz JA
    Gastroenterol Clin North Am; 2004 Jun; 33(2):171-89, vii. PubMed ID: 15177533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.
    Gionchetti P; Rizzello F; Annese V; Armuzzi A; Biancone L; Castiglione F; Comberlato M; Cottone M; Danese S; Daperno M; D'Incà R; Fries W; Kohn A; Orlando A; Papi C; Vecchi M; Ardizzone S;
    Dig Liver Dis; 2017 Jun; 49(6):604-617. PubMed ID: 28254463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases - author's reply.
    Ananthakrishnan AN
    Aliment Pharmacol Ther; 2015 Jul; 42(1):120. PubMed ID: 26040521
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: screening for adrenal suppression in paediatric inflammatory bowel disease - authors' reply.
    Philpott H; Dougherty MK; Dellon ES
    Aliment Pharmacol Ther; 2018 Oct; 48(8):885-886. PubMed ID: 30281837
    [No Abstract]   [Full Text] [Related]  

  • 10. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
    Lichtenstein GR; Sbreu MT; Cohen R; Tremaine W
    Rev Gastroenterol Mex; 2006; 71(3):351-401. PubMed ID: 17140062
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial: changing nature of paediatric IBD-new insights from Irish data. Author's reply.
    Hussey S
    Aliment Pharmacol Ther; 2017 Aug; 46(4):458-459. PubMed ID: 28707793
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial: trends in the epidemiology of inflammatory bowel disease in Korea - author's reply.
    Shim JO
    Aliment Pharmacol Ther; 2022 Oct; 56(7):1209-1210. PubMed ID: 36071011
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD.
    Haydek JP; Scott FI
    Aliment Pharmacol Ther; 2022 Sep; 56(5):896-897. PubMed ID: 35934853
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease.
    Zeng J; Gan HT
    Aliment Pharmacol Ther; 2019 Sep; 50(6):712-713. PubMed ID: 31456298
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial: the most commonly used IBD indices still fail to represent real life and subjective patient experience. Author's reply.
    Pariente B
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1203-1204. PubMed ID: 32424924
    [No Abstract]   [Full Text] [Related]  

  • 16. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
    Lichtenstein GR; Abreu MT; Cohen R; Tremaine W;
    Gastroenterology; 2006 Mar; 130(3):935-9. PubMed ID: 16530531
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply.
    Higgins PD
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):167-8. PubMed ID: 26387975
    [No Abstract]   [Full Text] [Related]  

  • 18. [Apheresis in inflammatory bowel disease. A valid option?].
    Cabriada JL
    Gastroenterol Hepatol; 2012 Jan; 35(1):22-31. PubMed ID: 22169354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Systemic corticosteroids in inflammatory bowel disease: are they really effective. What is their real toxicity?].
    Bastida G; Muñoz F
    Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():3-9. PubMed ID: 19087857
    [No Abstract]   [Full Text] [Related]  

  • 20. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
    Lichtenstein GR; Abreu MT; Cohen R; Tremaine W;
    Gastroenterology; 2006 Mar; 130(3):940-87. PubMed ID: 16530532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.